---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-045178"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:41:05.455280+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunovant announces positive initial Phase 1 data for IMVT-1402; IgG reduction without albumin or LDL-C changes

## Summary
- SC doses of IMVT-1402 achieved peak IgG reductions similar to batoclimab with no decrease in serum albumin or increase in LDL-C.
- In 300 mg MAD cohort, mean total IgG reduction from baseline was 63% after 4 weekly doses; no albumin drop or LDL-C rise observed.
- All adverse events were mild or moderate; no significant albumin reduction or LDL-C increase at any timepoint (all p>0.05).
- Dosing for 600 mg MAD cohort has recently begun; additional MAD data expected in November 2023.
- IMVT-1402 delivered as simple 2 mL SC injection at 150 mg/mL; SAD data showed potency similar to or greater than batoclimab.

## SEC filing metadata
- accession: 0001140361-23-045178
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123045178/0001140361-23-045178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123045178/ef20011235_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-045178
- JSON: https://secwatch.observer/filing/0001140361-23-045178.json
- Plain text: https://secwatch.observer/filing/0001140361-23-045178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.